A cancerous tumor of the mesothelium is known as malignant mesothelioma and also called as mesothelioma. The mesotheliomas can be initiated in at four different location of human body, those are pleural mesotheliomas are starts from chest, peritoneal mesotheliomas arises from abdomen, pericardial mesotheliomas from heart and mesotheliomas of tunica vaginalis from covering layer of testicles. The mesotheliomas can be treated with surgery, chemotherapy. In chemotherapy, drug is injected to intrapleurally or intraperitoneally. Increasing awareness about malignant mesothelioma treatment and growing incidence rate are expected to provide healthy growth to malignant mesothelioma market during the forecast period.
Global increase in prevalence rate of mesothelioma, and growing healthcare spending on cancer care and treatment are significantly contributing to the growth of malignant mesothelioma treatment market. Malignant mesothelioma is highly prevalent among geriatric population rather than other people and is one of the prominent factor which propels the growth of global malignant mesothelioma market. For instance, according to the cancer research. U.K., 2,667 new cases found in 2013 and 48% cases are founded above 75 years people. Though the malignant mesothelioma market is expected to generate significant revenue throughout the forecast period. High cost of medications and treatment methods and limited efficacy of treatment methods would act as major restraint for the malignant mesothelioma market. Going forward, commercialization of novel medications and introduction of advance treatment modalities to treat malignant mesothelioma would provide lucrative growth opportunity to the market during the forecaste period.
The global market for malignant mesothelioma is segmented on basis of treatment type, distribution channel, and region:
Substantial increase in geriatric population would propel the incidence rate of malignant mesothelioma, globally. The global malignant mesothelioma market is expected to have promising growth opportunities during the forecast period (2016-2026). This would provide prominent opportunity to global pharmaceutical companies which are focusing on commercializing novel treatment methods and advanced medications for malignant mesothelioma treatment.
On the basis of region, malignant mesothelioma market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the malignant mesothelioma market due to high prevalence rate followed by Europe. According to National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER), 2,500-3,000 new cases recording per year in the U.S. Increase in health care expenditure and growing number of geriatric population in Asia-Pacific countries such as Japan, China is anticipate to exhibit robust growth for malignant mesothelioma treatment in Asia Pacific region.
Some of the key market players in the manufacturing of the treatment products for malignant mesothelioma includes Eli Lilly and Company, Pfizer, Inc., Elder Pharmaceuticals, NATCO Pharma Limited, Dr. Reddy’s Laboratories Ltd. and Cipla Limited.
The report covers exhaustive analysis on:
Regional analysis includes